| 353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC A Jimeno, S Papa, M Haigentz, J Rodríguez-Moreno, J Schardt, M Fardis, ... Journal for immunotherapy of cancer 8 (Suppl 3), 2020 | 10 | 2020 |
| COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell … F Ravandi, A Kishtagari, HE Carraway, GJ Schiller, S Morris, A Cacovean, ... Journal of Clinical Oncology 40 (16_suppl), TPS7064-TPS7064, 2022 | 5 | 2022 |
| 187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours S Gettinger, H Kluger, A Schoenfeld, AB Warner, K He, A Sukari, ... Journal of Thoracic Oncology 16 (4), S799-S800, 2021 | 4 | 2021 |
| Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R/R) acute leukemia (AL): preliminary phase 1 data from the Covalent-101 study J Lancet, F Ravandi, P Montesinos, JC Barrientos, T Badar, A Alegre, ... Blood 142, 2916, 2023 | 3 | 2023 |
| Novel irreversible menin inhibitor, BMF-219, shows potent single agent activity in clinically relevant DLBCL cells P Somanath, D Lu, B Law, TC Archer, A Cacovean, JT Palmer, ... Blood 138, 4318, 2021 | 3 | 2021 |
| A phase II study of autologous tumor infiltrating lymphocytes (TIL; LN-144/LN-145) in patients with solid tumors J Chesney, A Cacovean, H Li, D Barton, M Fardis Annals of Oncology 29, x15-x16, 2018 | 3 | 2018 |
| P587: COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory acute leukemia, diffuse large B-cell lymphoma … F Ravandi-Kashani, A Kishtagari, H Carraway, G Schiller, E Curran, ... HemaSphere 6, 486-487, 2022 | 2 | 2022 |
| A phase 2 multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC). E Massarelli, Z Goldberg, A Cacovean, B Yadav, G Chen, M Jagasia, ... CANCER RESEARCH 81 (13), 2021 | 1 | 2021 |
| Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve … SS Thomas, GK In, B Doger, S Haefliger, J Martin-Liberal, Z Goldberg, ... Journal of Clinical Oncology 39 (15_suppl), 9537-9537, 2021 | 1 | 2021 |
| 188TiP A phase II multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC) E Massarelli, Z Goldberg, A Cacovean, B Yadav, G Chen, M Jagasia, ... Journal of Thoracic Oncology 16 (4), S800, 2021 | 1 | 2021 |
| COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung … C Fountzilas, SA Cohen, HL Duvivier, DS Hong, KS Pedersen, EP Pisick, ... Journal of Clinical Oncology 42 (3_suppl), TPS716-TPS716, 2024 | | 2024 |
| P2. 12-03 COVALENT-102: A Phase 1/1b Study of BMF-219, A Menin Inhibitor in Patients with Unresectable, Metastatic NSCLC, PDAC, and CRC S Patel, D Hong, SA Cohen, C Fountzilas, D Sommerhalder, S Radhi, ... Journal of Thoracic Oncology 18 (11), S363, 2023 | | 2023 |
| P-213 COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330) A Rosenberg, M Baljevic, AA Amor, J Barrientos, A Bashey, R Baz, ... Clinical Lymphoma Myeloma and Leukemia 23, S152-S153, 2023 | | 2023 |
| POSTER: AML-522 COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM … F Ravandi, J Lancet, AA Amor, T Badar, J Barrientos, A Bashey, ... Clinical Lymphoma Myeloma and Leukemia 23, S171, 2023 | | 2023 |
| AML-522 COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL … F Ravandi, J Lancet, AA Amor, T Badar, J Barrientos, A Bashey, ... Clinical Lymphoma Myeloma and Leukemia 23, S310-S311, 2023 | | 2023 |
| Abstract A003: COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC … SA Cohen, C Fountzilas, D Sommerhalder, S Patel, A Benson, K He, ... Molecular Cancer Research 21 (5_Supplement), A003-A003, 2023 | | 2023 |
| P-269: COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma … F Ravandi, H Carraway, J Khouri, A Kishtagari, E Curran, G Schiller, ... Clinical Lymphoma Myeloma and Leukemia 22, S185-S186, 2022 | | 2022 |
| A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell … F Ravandi-Kashani, A Kishtagari, H Carraway, E Curran, G Schiller, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
| Abstract CT210: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse … F Ravandi-Kashani, A Kishtagari, H Carraway, E Curran, G Schiller, ... Cancer Research 82 (12_Supplement), CT210-CT210, 2022 | | 2022 |
| P14. 04 A Phase 2 Multicenter Study of Iovance Autologous Tumor Infiltrating Lymphocytes (TIL, LN-145) Cell Therapy in Patients With Metastatic NSCLC E Massarelli, A Schoenfeld, J Chesney, Y Hong, P Lammers, J Nieva, ... Journal of Thoracic Oncology 16 (10), S1012, 2021 | | 2021 |
